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abstract
Background and Aims: severe, medically uncontrollable gastroparesis is a rare entity, 
which can be treated using a high-frequency gastric electric stimulator implanted surgically. 
previous follow-ups have proven positive outcomes with gastric electric stimulator in 
patients with gastroparesis. the aim of this study was to evaluate the efficacy and safety 
of gastric electric stimulator in patients, in whom gastroparesis could not be controlled by 
conservative means in our country.
Materials and Methods: this is a retrospective multi-center cohort comprising all 
patients who had been implanted gastric electric stimulator for severe, medically refractory 
gastroparesis during 2007–2015 in finland.
Results: fourteen patients underwent implantation of gastric electrical stimulator 
without any postoperative complications. laparoscopic approach was used in 13 patients 
(93%). prior implantation, all patients needed frequent hospitalization for parenteral 
feeding, 13 had severe nausea, 11 had severe vomiting, 10 had notable weight loss, and 6 
had frequent abdominal pain. after operation, none of the patients required parenteral 
feeding, 11 patients (79%) gained median of 5.1 kg in weight (p < 0.01), and symptoms 
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InTRODUCTIOn
Gastroparesis is a disorder of gastric emptying with-
out underlying mechanical obstruction (1). Main 
symptoms include early satiety, bloating, upper 
abdominal pain, nausea, and vomiting leading sec-
ondarily to esophagitis and weight loss. Three etiol-
ogy categories exist: diabetic, idiopathic, and 
postoperative. While the idiopathic form is the most 
common, the diabetic form leads to most severe symp-
toms (2, 3).
The diagnosis of gastroparesis is based on typical 
symptoms when mechanical obstruction is ruled out. 
Gastric emptying can be measured by scintigraphy, 
13C-octanoic acid breath test, or dual-tracer scintigra-
phy (4–6). In mechanical obstruction, usually empty-
ing of both solids and liquids is slow, but in 
gastroparesis emptying of liquids may be normal.
Conservative therapy of gastroparesis consists of 
dietary and medical treatments, which often are suf-
ficient. Generally, small frequent meals with high 
protein with low fiber and fat content are recom-
mended (7, 8). Metoclopramide, erythromycin, or 
domperidone can be used as prokinetic agents . 
Despite symptom relief, there is no clear association 
with enhancement of gastric emptying (9). The 
5-HT4-agonist prucalopride has been proven to accel-
erate gastric emptying in healthy subjects and may 
be considered for treatment of gastroparesis (10). 
Furthermore, prucalopride is effective in treating 
obstipation, which may also relieve symptoms of 
gastroparesis (11–13). Pyloric botulinum toxin injec-
tions have been useful in open label studies, but not 
in a randomized, controlled study (14, 15). Even 
transpyloric stenting and total gastrectomy have 
been suggested as a treatment option for gastropare-
sis (16, 17).
Although most patients with gastroparesis have 
sufficient relieve by conservative means, in a small 
subset of patients it is uncontrollable by medical treat-
ment. For these patients, a gastric electrical stimulator 
(GES) (Enterra®, Medtronic, Minneapolis, Mn, USA) 
has become available commercially (18).
The aim of this study was to assess the efficacy 
and safety of implantation of GES in patients with 
medically uncontrollable gastroparesis. We included 
all patients who had undergone GES implantation in 
Finland between 2007 and 2015.
MATERIALS AnD METHODS
PATIEnT POPULATIOn AnD DATA SELECTIOn
The hospitals, which had implanted GES in Finland, 
were obtained by personal communication with the 
manufacturer’s Finnish representative (Enterra, 
Medtronic). Four hospitals (Helsinki and Oulu University 
Hospitals; Lapland and Seinäjoki Central Hospitals) 
were identified and contacted, and patients who had 
undergone GES implantation were included in this retro-
spective cohort study. The patients were identified from 
prospective registers (Helsinki 10 patients, Lapland 2 
patients, Oulu 1 patient, and Seinäjoki 1 patient).
The diagnosis of gastroparesis had been verified by 
dual-tracer scintigraphy in 13 patients performed 
directly after gastroscopy. The diagnosis required a 
pathologically long gastric emptying time for solids 
(solid intake half-time >135 min) (6), but liquid gastric 
emptying could be normal. no control scintigraphy 
studies were performed considering the x-ray burden 
to individual patients. Patients with no or mild symp-
toms were considered as marked responders, patients 
with moderate symptoms as partial responders, and 
those with severe symptoms were considered failures.
SURGICAL TECHnIqUE
Laparoscopic operation was performed in a standard 
fundoplication position and setup. 5 cm incision for 
the Enterra device was made to the upper left quad-
rant of the abdomen, and a 10 mm trocar was inserted 
in the upper right quadrant. Two electrodes were 
applied to the anterior wall of the stomach 9 and 10 cm 
orally from the pylorus respectively. Correct position 
of the electrodes in the muscle layer of the stomach 
was confirmed by intraoperative gastroscopy. The 
electrodes were attached to the serosal surface of the 
stomach using silicon bands fixed with non-absorba-
ble sutures and clips. The electrodes were taken out of 
the abdominal cavity and a subcutaneous cavity was 
created for the Enterra device. The impedance of the 
device was measured to ascertain its proper function 
before it was buried into the subcutaneous cavity.
PATIEnT FOLLOW-UP
The patients were followed at the gastroenterology 
outpatient clinic. The last follow-up date was defined 
were relieved markedly in 8 and partially in 3 patients (79%). Of partial responders, two 
continued to experience occasional vomiting and one mild nausea. five patients needed 
medication for gastroparesis after the operation. One patient did not get any relief of 
symptoms, but gained 6 kg in weight. no major late complications occurred.
Conclusion: gastric electrical stimulator seems to improve the nutritional status and give 
clear relief of the symptoms of severe, medically uncontrollable gastroparesis. given the 
low number of operations, gastric electrical stimulator seems to be underused in finland.
Key words: High-frequency gastric electric stimulation; gastroparesis; laparoscopy; multi-center cohort; 
complications; Finland
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as the last time physician either met or called the 
patient. The study was approved by the institutional 
review boards of participating centers.
STATISTICAL AnALySIS
Change of weight was analyzed with the Wilcoxon 
matched-pairs signed rank sum test. The statistical 
analysis was performed by SPSS software.
RESULTS
Fourteen patients (seven males, mean age: 40 years 
(range 24–54)) were included in the study (Table 1). 
The etiology of gastroparesis was diabetes (n = 11), idi-
opathic (n = 1), or postoperative (n = 2). Type 1 diabetes 
(n = 9) was the most common, whereas one patient had 
type 2 diabetes, and one patient had diabetes due to 
chronic pancreatitis. One patient had undergone fun-
doplication two times with possible vagal nerve injury 
and in one patient symptomatic gastroparesis was 
diagnosed after several abdominal operations.
Every patient had undergone careful diagnostic 
work-up and medical treatment before implantation 
of GES. All patients had undergone gastroscopy. 
Scintigraphy had been performed in 13 patients (93%) 
and all these patients had delayed solid gastric empty-
ing. Furthermore, all patients had undergone some 
form of abdominal imaging, ultrasound was per-
formed in 10 patients (71%), computed tomography in 
7 patients (50%), and magnetic resonance imaging in 8 
patients (57%). Thirteen patients (93%) had undergone 
imaging with several modalities.
Medical therapy was tried in all patients. Twelve 
patients (86%) used proton pump inhibitors, eleven 
patients (79%) used cisapride or prucalopride, eight 
patients (57%) used erythromycin, and seven patients 
(50%) used metoclopramide. Twelve patients (86%) 
used several types of medications.
nausea and vomiting were the leading symptoms, 
which had led to hospital admissions and periods of 
parenteral nutrition in 13 patients. One patient had 
abdominal pain as the main symptom. The number of 
hospital admissions varied from 2 to 13 times prior 
implantation of gastric stimulator. Weight of the 
patients varied across the preoperative period and 
lowest weight during conservative treatment is shown 
in Fig. 1. Eleven patients gained median of 10 (inter-
quartile range (IqR) 5.3–14.3) kg in weight during 
intravenous nutrition treatment prior to operation, 
calculated after the symptoms of severe gastroparesis 
and the conservative treatment had started (missing 
data n = 3). Six (43%) patients had also abdominal 
pain. Median serum albumin was 38.7 (IqR 33.9–
42.7) g/L preoperatively. Five patients had albumin 
less than 35 g/L preoperatively.
OUTCOME
Thirteen GES were implanted using laparoscopic 
approach. One implantation was done through lapa-
rotomy due to several prior abdominal operations. no 
postoperative complications occurred. Discomfort at 
the battery pocket site was reported by one patient at 
1-month follow-up. Median postoperative length of 
hospital stay was 4 (IqR 2–5) days, which was mainly 
for testing and adjusting the device. The patients were 
followed for median 36 (IqR 10–63) months. Two 
patients were lost to follow-up.
Interestingly, symptoms slowly recurred during 
control visits in four patients. It was found out that 
their GES battery was exhausted. These patients 
underwent battery-change reoperation. For one 
patient, this was done twice. Battery-change restored 
the functionality of the stimulator and relieved the 
symptoms in all four patients. no surgical complica-
tions were related to reoperations.
Symptoms of gastroparesis were relieved markedly 
in eight and partially in three patients (Table 2). Two 
partial responders continued to vomit occasionally 
TABLE 1.
Patient demographics.
n (%)
Age, years, mean (range) 40 (24–54)
Males 7 (50)
Etiology of gastroparesis
 Type 1 diabetes 9 (64)
 Type 2 diabetes 1 (7)
 Post-pancreatitis diabetes 1 (7)
 Postoperative 2 (14)
 Idiopathic 1 (7)
Medications
 Cisapride/prucalopride 11 (79)
 Erythromycin 7 (50)
 Metoclopramide 8 (57)
 Proton pump inhibitors 12 (86)
Investigation
 Gastroscopy 14 (100)
 Abdominal ultrasound 10 (71)
 Computer tomography 7 (50)
 Magnetic resonance imaging 8 (57)
 Scintigraphy 13 (93)
Fig. 1. Mean weight (kg) of patients who attended all three weight 
measurements (n = 11).
*P < 0.05, **P < 0.01.
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and one had mild nausea after GES implantation. The 
patient who underwent open surgery continued to 
have abdominal pain, but vomiting decreased mark-
edly and the patient gained 6 kg in weight after 
implantation. However, abdominal pain continued 
lead to duodenojejunostomy 6 months after GES 
implantation.
Eleven patients (79%) gained median 5.1 (IqR 
0–8.0) kg in weight (missing data n = 3), after GES 
implantation (Fig. 1). Five out of ten patients (50%) 
were without medication for gastroparesis at the latest 
follow-up (missing postoperative medication data 
n = 4).
Among patients with diabetic gastroparesis (n = 11), 
median HbA1c level 6 months after the implantation of 
GES was 67 (IqR 53–86) mmol/mol compared to the 
preoperative median value of 66 (54–78) mmol/mol 
(missing data n = 5). Thus, no change in HbA1c levels 
was detected postoperatively. However, hypoglycemic 
episodes requiring hospital treatment were very 
few after the GES implantation. One patient with dia-
betic gastroparesis continued to have hypoglycemic 
episodes needing hospital treatment and one other 
patient had one such episodes, while others did not 
(missing data n = 3).
DISCUSSIOn
As only 14 patients have received GES in our study 
period, it seems that this treatment modality is under-
used in Finland. All patients were dependent on fre-
quent parenteral nutrition indicating that GES is 
considered as the very last resort in the treatment of 
gastroparesis. The results of GES for treatment of 
medically uncontrollable gastroparesis are encourag-
ing. none of the patients required parenteral nutrition 
after implantation, 80% gained weight, 70% experi-
enced their symptoms relieved, and half of the patients 
could wean off medication. Furthermore, the implan-
tation was primarily carried out laparoscopically with 
no complications indicating safe procedure with mini-
mal length of hospital stay required.
Very interesting evidence for the benefit of GES on 
the symptoms is provided by the four patients whose 
TABLE 2
Symptoms and weight gain preoperatively and at the last follow-up visit.
Patient number Sex
Age  
(years)
Symptoms before GES 
implantation
Symptoms at the last follow-up 
visit
Weight change after 
implantation (kg)
Follow-up 
(months)
1 Male 42 Extreme vomiting and 
feeling of fullness, parenteral 
nutrition
Symptoms relieved. 1 +2.9 2.5
2 Male 51 Vomiting, parenteral 
nutrition
Variable, need for adjustment of 
GES parameters. 2
−1.0 30.2
3 Female 52 Weight loss and need of 
parenteral nutrition
no vomiting or nausea. Mild 
obstipation. 1
+12.3 101.1
4 Male 51 Vomiting, glucose balance 
disturbance, parenteral 
nutrition
nausea and vomiting only 
occasionally. 2
+6.0 56.8
5 Male 30 nausea and vomiting, 
parenteral nutrition
Dyspepsia. 1 +14.0 41.8
6 Male 36 nausea and vomiting, 
parenteral nutrition
Mild nausea relieved, no 
vomiting. 1
+2.1 10.7
7 Female 29 nausea, vomiting, and 
weight loss, parenteral 
nutrition
Symptoms relieved. 1 nA 45.2
8 Female 24 nausea, vomiting and weight 
loss, parenteral nutrition
Occasional vomiting. 2 +5.1 9.2
9 Male 40 nausea, vomiting, weight 
loss, and recurrent hospital 
treatment
Symptoms relieved, patient lost 
to follow-up
0 23.0
10 Female 45 Vomiting, abdominal pain, 
nausea, and recurrent 
hospital treatment
Asymptomatic. 1 +8.0 3.4
11 Female 40 Vomiting and abdominal 
pain, parenteral nutrition
Asymptomatic. 1 0 30.5
12 Female 54 Vomiting and recurrent 
hospital admissions
Abdominal pain, no vomiting. 3 +6 50.0
13 Male 36 nausea, vomiting, parenteral 
nutrition
Asymptomatic. 1 nA 116.5
14 Female 31 nausea, vomiting, diarrhea, 
parenteral nutrition
Lost to follow up because 
patient moved hospital district 
after operation, no vomiting
nA 81.4
GES: gastric electrical stimulator; nA: not available; 1: marked response; 2: partial response; 3: failure.
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GES battery was exhausted during the follow-up 
period. In these patients, symptoms recurred, but 
could again be relieved by battery-change. It thus 
seems that GES has long standing effect. A similar 
worsening of symptoms was also seen in a study of 33 
patients with diabetic and idiopathic gastroparesis 
with GES implanted when the device was turned off 
(19). In two other randomized, double-blinded con-
trolled studies, GES also significantly reduced vomit-
ing during the 12 months open follow-up but there 
was no significant difference between the on and off 
periods during double-blind phase of the study (20, 
21). In diabetic gastroparesis, GES implantation had 
no significant effect on HbA1c values measured after 
six 12 months of therapy (20).
Other centers have published similar good results 
of gastric electrical stimulation. McCallum and cow-
orkers followed 182 patients for 10 years. Patients 
were similar compared to our study. Symptoms were 
significantly improved, but there was no statistical 
difference in gastric emptying before and after gas-
tric electrical stimulation (22). In our study, the post-
operative gastric emptying was not evaluated in all 
patients, but in those patients it was assessed there 
were no difference. The mechanisms of action of 
GES are not well understood. It does not seem to 
accelerate gastric emptying, but might act by affect-
ing afferent vagal neural activity to control 
central nervous system mechanisms of nausea and 
vomiting (23).
The cost of the device is currently high and for this 
reason, the patients are highly selected. On individual 
basis, it is difficult to predict in which patients GES is 
effective. Results seem to be better in diabetic gastro-
paresis compared to idiopathic or postsurgical gastro-
paresis (24). In recent paper, Heckert and coworkers 
evaluated 151 patients with refractory gastroparesis 
who underwent GES. Improvement with symptoms 
was detected in 75% of patients with 43 being at least 
moderately improved and diabetics responded better 
than nondiabetic patients (24).
There are limitations in this study. This was a retro-
spective series with small number of patients. The 
follow-up time was relatively short (median 3 years). 
In consequence, it remains unknown how long GES 
will relieve the symptoms and whether the effect will 
wear off at some point.
In conclusion, GES seems to be effective treatment 
modality for severe gastroparesis in selected patients. 
Laparoscopy is an efficient and a safe method for GES 
implantation. GES implantation is scarce in Finland.
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